COPD A New Look at an Old Disease
|
|
- Kelly Lester
- 5 years ago
- Views:
Transcription
1 A New Look at an Old Disease Disclosures Research support to institution from Roche/Genentech, GSK, Astra Zeneca, Cheisi, Sunovion, Mylan, Boehringer Ingelheim Research support from the American Lung Association and NIH Nicola A. Hanania, MD, MS, FCCP, FRCP(C) Associate Professor of Medicine Pulmonary and Critical Care Medicine Director, Airway Clinical Research Center Consultant Roche/Genentech, Astra Zeneca, Boehringer Ingelheim, Novartis Speaker Bureau: Genentech, Sunovion GOLD: Global Initiative for Chronic Obstructive Lung Disease GOLD definition of 1 Common, preventable, treatable partially reversible Characterized by persistent airflow limitation Usually progressive and disabling Associated with enhanced chronic inflammatory response in airways/lung to noxious particles or gases is heterogeneous 2 Multiple risk factors, phenotypes, comorbidities Exacerbations and comorbidities contribute to severity The New Look of Epidemiology Pathophysiology Diagnosis and Assessment Management Novel targets for therapy 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Goh F et al. Expert Rev RespirMed. 2013;7(6):
2 : The Old Look Perception 3,4,5 in Younger Patients and Women Is on the Rise Reality is a disease of the elderly 1 is a disease of men 2 Reality: afflicts the working age population. Reality: is also a disease of women. 1 Tinkelman, et al. Am J Manag Care. 2003;9: Chapman KR. Clin Chest Med. 2004;25: Rennard SI. New Engl J Med. 2004;350: Kleinschmidt P. Chronic obstructive pulmonary disease and emphysema. Available at 5 Rennard SI. New Engl J Med. 2004;305: Mannino, et al. MMWR. 2002; 51(6 suppl):1-16. Netter illustrations used with permission from Icon Learning Systems, a division of MediMedia USA, Inc. All rights reserved. The Impact of in the United States In 2010, accounted for million physician office visits/y 1.5 million ED visits 699,000 hospital discharges Costly 2 Direct: $27 billion/y Indirect: $20 billion/y 3rd leading cause of death 3 4th leading cause of hospital readmissions 4 The New Look of Epidemiology Pathophysiology Diagnosis and Assessment Management Novel targets for therapy 1. Ford ES et al. Chest. 2013;144(1): Morbidity & Mortality 2012 Chart Book. pdf. 3. HeronM. Natl Vital Stat Rep. 2012;60(6): Jencks SF et al. N Engl J Med. 2009; 360:
3 : The New Look Risk Factors for Exposure to inhaled particles: Tobacco smoke (active and passive) Occupational dusts, organic and inorganic Indoor air pollution from heating and cooking with biomass in poorly ventilated dwellings Outdoor air pollution Susceptibility genes Poor lung growth and development Oxidative stress Female gender Age Respiratory infections Low socioeconomic status Poor nutrition Co morbidities Agusti A, Vestbo J. AJRCCM 2011;184: : Oxidative Stress is Central to the Destruction of Pulmonary Tissue Inflammatory and Cellular Mechanisms in due to Cigarette Smoking Auto Barnes PJ. Clin Chest Med 35 (2014) Chung KF, et al. Eur Respir J. 2008;31:
4 : A Multicomponent Disease Pathophysiology of Mucus hypersecretion Reduced mucociliary transport Mucosal damage Increased numbers of inflammatory cells/ activation: CD8+ T-lymphocytes Monocytes/ macrophages Neutrophils Mast cells Elevated inflammatory mediators: IL-8, TNF-, LTB-4, and oxidants Protease/anti-protease imbalance Mucociliary dysfunction Airway inflammation Airflow limitation Structural changes Systemic component Goblet cell hyperplasia/ metaplasia Mucous gland hypertrophy Increased smooth muscle mass Airway fibrosis Alveolar destruction Poor nutritional status Reduced BMI Impaired skeletal muscle Weakness Wasting Loss of alveolar attachments Loss of elastic recoil Increased smooth muscle contraction Hyperinflation, central to the pathophysiology of (ie, increased airway resistance), correlates more directly with patient-reported outcomes Hypoxemia Anxiety Patientreported outcomes Tachypnea Dyspnea Airflow obstruction Air trapping Hyperinflation Ventilatory requirement Activity limitation Poor health-related quality of life Exacerbations Deconditioning Cooper CB. Respir Med. 2008;20:1-10. The New Look of is Underdiagnosed and Undertreated Epidemiology Pathophysiology Diagnosis and Assessment Management Novel targets for therapy 1. NIH, NHLBI. Morbidity and Mortality: 2009 Chartbook on Cardiovascular, Lung and Blood Diseases. 2.Make B et al. Int J Chron Obstruct Pulmon Dis. 2012;7: Mapel DW, et al. Int J Chron Obstruct Pulmon Dis. 2011; 6:
5 Natural History of Significant Drops in Lung Function Are Often Required for Patients to Become Severely Symptomatic PT # 1 59 y FEV1: 28 % PT # 2 63 y FEV1: 33 % PT # 3 70 y FEV1: 35 % PT # 4 72 y FEV1: 34 % MRC: 2/4 MRC: 2/4 MRC: 3/4 MRC: 4/4 FEV 1 (% predicted at age 25 years) Dyspnea, Cough Exercise Intolerance Exacerbations Hospitalizations Systemic Effects Respiratory Failure Pulm Hypertension PaO2: 70 mmhg 6MWD: 540 mt BMI: 30 PaO2: 57 mmhg PaO2: 66 mmhg 6MWD: 348mt 6MWD: 230 mt BMI: 21 BMI: 34 Heterogeneity PaO2: 60 mmhg 6MWD: 140 mt BMI: FEV1 < 35% predicted Courtesy of C.Cote, MD Recent Trials to Identify Phenotypes Airway Disease Emphysema BMI < 21 BMI >35 Sedentary Active 5
6 Phenotypes Disease attributes that describe the diverse symptoms and outcomes of patients Ideal Phenotypic Construct Frequent Exacerbations Systemic Inflammation Chronic Hypoxemia Exercise/ Activity Intolerance/ Hyperinflation Chronic Cough and Sputum Chronic Respiratory Failure Comorbidities Cardiac, Nutritional Radiologic Airway (CB, bronchiectasis), Emphysema Asthma Overlap Syndrome (ACOS) Symptom Burden Chen X et al. Front. Med. 2013;7(4): Oga T et al. Chest. 2005;128: Westwood M et al. Respir Res. 2011;12:40. Therapeutic implications Prognostic implications Han MK, et al. Am J Respir Crit Care Med. 2010;182(5): Assessment of Patient assessment criteria* Global Strategy for Diagnosis, Management and Prevention of : Assessment of Assess symptoms Airflow Limitation Spirometry for diagnosis and assessment Symptoms Validated patient questionnaires (mmrc and CAT) Exacerbation Risk History of exacerbations or spirometric classification *Pharmacological management of should also include an assessment of potential patient comorbidities mmrc: Modified Medical Research Council Dyspnea Scale CAT: Assessment Test Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
7 Assessment of : Symptoms Assessment Test (CAT) Grade Description of Breathlessness 0 I only get breathless with strenuous exercise 1 I get short of breath when hurrying on level ground or walking up a slight hill 2 On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace 3 I stop for breath after walking about 100 yards or after a few minutes on level ground 4 I am too breathless to leave the house or I am breathless when dressing Modified Medical Research Council Dyspnea Score 0 1 Symptoms More Severe GOLD Website. Updated December 2011 Global Strategy for Diagnosis, Management and Prevention of : Assessment of Assess symptoms Assess degree of airflow limitation using spirometry Severity of Obstruction Post-bronchodilator FEV 1 /FVC <70% Worse obstruction IV: Very Severe FEV 1 <30% III: Severe FEV 1 30% to 49% II: Moderate FEV 1 50% to 79% I: Mild FEV 1 80% Assessment of : Lung Function In patients with FEV 1 /FVC < 0.70: GOLD 1: Mild GOLD 2: Moderate GOLD 3: Severe FEV 1 > 80% predicted 50% < FEV 1 < 80% predicted 30% < FEV 1 < 50% predicted GOLD 4: Very Severe FEV 1 < 30% predicted *Based on Post-Bronchodilator FEV 1 GOLD Website. Updated December
8 Global Strategy for Diagnosis, Management and Prevention of : Assessment of Assess symptoms Assess degree of airflow limitation using spirometry Assess risk of exacerbations Lower quality of life Frequent Exacerbations Drive Disease Progression Increased inflammation Patients with frequent exacerbations Increased mortality rate Increased risk of recurrent exacerbations Faster disease progression Wedzicha JA & Seemungal TA. Lancet 2007;370: ,; Donaldson GC & Wedzicha JA. Thorax 2006;61: Increased likelihood of hospitalization Risk GOLD: Combined Assessment Assessment Using Symptoms, Breathlessness, Spirometric Classification, and Risk of Exacerbations a (GOLD Classification of Airflow Limitation) C High risk, Less symptoms A D High risk, More symptoms B 2 or 1 leading to hospital admission 1 (not leading to hospital admission) 1 Low risk, Less symptoms Low risk, More symptoms 0 CAT < 10 CAT 10 Symptoms mmrc 0 1 mmrc 2 Breathlessness Risk (Exacerbations/Year) Global Strategy for Diagnosis, Management and Prevention of : Assessment of Assess symptoms Assess degree of airflow limitation using spirometry Assess risk of exacerbations Assess comorbidities a When assessing risk, choose the highest risk according to GOLD grade or exacerbation history. 8
9 Comorbidities of Lung cancer Anxiety, depression Exploring the Links Between and Its Comorbidities Pulmonary hypertension Cardiovascular disease Anemia Diabetes Metabolic syndrome Cachexia Kao C, Hanania NA. in: Crapo J, ed. Philadelphia, PA: Current Medicine Group;2008. Peripheral muscle wasting and dysfunction Osteoporosis Peptic ulcers GI complications These comorbid conditions may influence mortality and hospitalizations; the patient should be assessed for them routinely and treated appropriately. Risk Factors Smoking and lifestyle factors Genetic susceptibility Chronic airway infection Acute exacerbations Mechanisms Airway and systemic inflammation Lung hyperinflation and endothelial dysfunction Oxidative stress Patel AR, Hurst JR. Expert Rev Respir Med. 2011;5(5): Comorbidities Ischemic heart disease Stroke and heart failure Hypertension and diabetes Muscle weakness and osteoporotic fractures Depression Outcomes Worse symptoms Worse health status Reduced activity Reduced survival Comorbidities of and Systemic Inflammation Assessing Comorbidities in Look for Comorbidities Look for If Smoker Barnes PJ. Clin Chest Med 35 (2014)
10 The New Look of Goals of Management Epidemiology Pathophysiology Diagnosis and Assessment Management Novel targets for therapy Airflow Limitation Symptom Burden Exacerbations Functional Limitations Reduce Hospital Admissions and Mortality Improve Lung Function Slow FEV1 Decline Improve Symptoms Prevent and Manage Exacerbations Improve Health Status and Exercise Tolerance Adapted from Global Initiative for Chronic Obstructive Lung Disease; (GOLD) Improving Outcomes in Early diagnosis and accurate assessment Identifying patients at risk Using appropriate diagnostic approaches, ruling out other mimickers Early treatment Implementing optimal management Reducing exposures to risk factors and triggers Non pharmacological approaches Pharmacological treatments Incorporating self management skills through education and collaboration with a health care team Improve adherence Nonpharmacologic Therapy To Manage Smoking Cessation Oxygen Therapy Patient Education Pulmonary Rehabilitation Vaccination Surgical and Nonsurgical Alternatives Rice K, et al. Clin Chest Med. 2014;35(2): ; Decramer M, et al. Respir Med. 2011;105(11): Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated
11 Non pharmacological Options for Patient Group Description Essential A Low risk, fewer symptoms GOLD 1 2 <1 Exacerbation mmrc 0 1 or CAT <10 B Low risk, more symptoms GOLD 1 2 <1 Exacerbation mmrc >2 or CAT >10 C High risk, fewer symptoms GOLD 3 4 >2 Exacerbations mmrc 0 1 or CAT <10 Smoking cessation for all patients who smoke The key intervention for smokers Can include pharmacologic treatment Pulmonary rehabilitation D High risk, more symptoms GOLD 3 4 >2 Exacerbations mmrc >2 or CAT >10 Exercise Training Involves the measurement of a number of physiologic variables, including maximum oxygen consumption, maximum heart rate, and maximum work performed Components of Pulmonary Rehabilitation Programs Pulmonary Rehabilitation Programs Nutrition Counseling Important determinant of symptoms, disability, and prognosis in ; a reduction in BMI is an independent risk factor for mortality in patients with Education Specific contributions of education to the improvements seen after pulmonary rehabilitation remain unclear Recommended Depending on local guidelines Physical activity Influenza vaccination Pneumococcal vaccination Assessment and Follow-up Adapted from Global Initiative for Chronic Obstructive Lung Disease; (GOLD) BMI=body mass index. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated Accessed April 9, Outcomes of Pulmonary Rehab in Reduces dyspnea Improves deconditioning, muscle fatigue Increases exercise capacity Improves quality of life Improves depression Reduces acute exacerbations. Reduces hospitalizations May reduce mortality Does not improve PFTs or ABGs Pharmacological Management of Guideline recommended treatment Improves lung function Minimizes symptoms Improves QoL Prevents exacerbations Wide variety of options including new agents Appropriate treatment selection hinges on GOLD staging Before stepping up/modifying treatment, re evaluate Treatment goals Clinical phenotype Comorbidities Adherence 1 British Thoracic Society. Thorax. 2001; 56: American Thoracic Society. Am J Respir Crit Care Med. 1999;159: Guell R, et al. Chest. 2000;117: Saey D, et al. Am J Respir Crit Care Med. 2003;168: Casaburi R. Am J Respir Crit Care Med. 2003;168: Casaburi R, et al. Am J Respir Crit Care Med. 1997;155: Griffiths TL, et al. Lancet. 2000;355: Cote CG, et al. Am J Respir Crit Care Med. 2003;167:A38. 11
12 Pharmacological Agents Approved in the U.S. Pharmacological Treatment Options Short acting β-agonists (SABA) Albuterol Pirbuterol Levalbuterol Bronchodilators Anticholinergic (SAMA) Ipratropium Long acting β-agonists (LABA) Salmeterol Formoterol Arformoterol Indacaterol Oladaterol Anticholinergic (LAMA) Tiotropium Aclidinium Umeclidinium Glycopyrrium LABA +LAMA Umeclidinium +Vilanterol Tiotropium + Oladaterol Glycopyrrinium _Indacaterol Anti Inflammatory ICS+LABA Fluticasone + Salmeterol Budesonide +Formoterol Fluticasone Fuorate +Vilanterol PDE 4 Inhibitors Roflumilast Systemic Steroids Prednisone Methylprednisolone Theophylline Adapted from: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Inhaler Devices Available in the U.S. Strategies to Ensure Adherence A large proportion (49-76%) of patients use their inhalers incorrectly GOLD guidelines recommend rechecking inhaler technique at each patient visit Ellipta 1.Newman SP. Eur Respir Rev. 2005;14:96, Molimard M, et al. J Aerosol Med. 2003;16(3): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
13 The New Look of Epidemiology Pathophysiology Diagnosis and Assessment Management Novel targets for therapy Unmet Needs with Current Interventions Current pharmacotherapies do not change the natural history of Many patients remain symptomatic with current therapies Inadequate adherence with inhaled therapy is a major cause of poor clinical outcomes in the treatment of Cost, compliance, and safety are significant issues Novel Pharmacological Targets in Novel formulations of existing medications Ultra LABAs (indacaterol, oladaterol) Ultra LAMAs (aclidinium, umeclidinium, glycopyrinium) LABA/LAMA combinations (vilanterol/umeclidinium, indacaterol/glycopyrrolate, formoterol/glycopyrrolate) LABA/ICS combinations (vilanterol/fluticasone) Nebulized bronchodilators and combination therapies MABAs Drugs Used in Treatment of Comorbidities That May Be Useful in Macrolides Statins ACE Inhibitors Beta blockers Peroxisome proliferator activated receptor (PPAR) agonists 13
14 Smoking Cessation Nicotine antagonists Vaccination Inflammosome Inhibitors Anti proteases: Neutrophil elastase MMP9 inhibitors Chemokine Antagonists Antioxidants Reversal of Steroid Resistance PDE inhibitors Epigenetic modulators Mediator Antagonists (TNF, IL 17, IL5, IL 13 antibodies) Kinase inhibitors Antibiotics Phagocytosis Antifibrotic: Regeneration: Mucoregulators: Targeting TGFβ Stem Cell EGFR inhibitors PPR agonists Retinoic Acid Barnes PJ. Nature Rev Drug Discovery 2013; 12: 543 Flow regulation Tissue compression Bronchoscopic Approaches to LVR Zephyr Endobronchial Valves (EBV) PulmonX Intrabronchial Valves (IBV) Spiration RePneu Lung volume reduction coil (LVRC) PneumRx AeriSeal Polymeric Lung Sealant Aeris InterVapor Bronchoscopic Thermal Vapor Ablation (BTVA) Uptake One way valve leads to atelectasis. One way valve leads to atelectasis. Coil reduces lung volume by coiling and compressing disease tissue. Tissue sealant flows into alveolar compartment, polymerizes and seals target area. Heated water vapor produces thermal reaction with localized inflammation followed by fibrosis. Summary continues to be a major public health problem The pathophysiology of involves chronic airway inflammation and lung destruction driven by several inflammatory cells and mediators is a heterogenous disease with multiple phenotypes Phenotypic characterization of will improve personalized approach the disease Summary Clinical approach to includes assessment of symptoms, lung function, exacerbation risk and comorbidities Several non pharmacological and pharmacological interventions are available which should be implemented according to disease severity Multiple novel targets of therapy are being evaluated and may be available in the future 14
Objectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationImplementing GOLD COPD Guidelines
Implementing GOLD COPD Guidelines Nicola A. Hanania, MD, MS, FCCP, FERS Associate Professor of Medicine Pulmonary and Critical Care Medicine Director, Airways Clinical Research Center Disclosure Information
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationWhat is this patient s diagnosis?
Asthma and COPD KANTA VELAMURI, MD ASSOCIATE PROFESSOR OF MEDICINE PULMONARY, CRITICAL CARE AND SLEEP MEDICINE SECTION MICHAEL E. DEBAKEY VA MEDICAL CENTER BAYLOR COLLEGE OF MEDICINE Disclosures None Case
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012
COPD Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012 Attitude It is a disease on which a good deal of wholly, unmerited
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationUPDATE ON GOLD GUIDELINES IN COPD
UPDATE ON GOLD GUIDELINES IN COPD GERARD J. CRINER, MD, FACP, FACCP PROFESSOR, THORACIC MEDICINE & SURGERY TEMPLE UNIVERSITY SCHOOL OF MEDICINE PHILADELPHIA, PA Gerard J. Criner, MD, is Professor and Founding
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationFighting for Air, In Emphysema
Fighting for Air, The Mechanism of Shortness of Breath In Emphysema Albert A. Rizzo, MD FCCP FACP Speaker, Nationwide Assembly of the American Lung Association & Section Chief Pulmonary/Critical Care Medicine
More informationPathophysiology of COPD 건국대학교의학전문대학원
Pathophysiology of COPD 건국대학교의학전문대학원 내과학교실 유광하 Rate per 100 0,000 population 550 500 450 400 350 300 250 200 150 100 50 0 Heart disease Cancer Stroke 1970 1974 1978 1982 1986 1990 1994 1998 2002 Year of
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationGOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation George Anderson, PhD Sr. Medical Science Liaison MA-AZAP ML-4006-US-0212 Approved 11/16 Glob al Strategy for the Diagnosis, Management,
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationCOPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationAt-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)
At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationLVRS and Endobronchial Therapy for Emphysema: Is it Still Viable?
LVRS and Endobronchial Therapy for Emphysema: Is it Still Viable? Malcolm M. DeCamp, MD Fowler McCormick Professor of Surgery Feinberg School of Medicine Chief, Division of Thoracic Surgery Disclosures
More informationKaren Meyerson, MSN, APRN, NP C, AE C
Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) June 2015 Karen Meyerson, MSN, APRN, NP C, AE C Patient Education The goal of all patient education is to help patients take the actions
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationWINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT
WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT Thursday, October 25, 2018 Sarah Sungurlu DO Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures I have no actual
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationDisclosures. Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease May 14, 2016 Orlando, FL COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United States. Alarmingly, COPD recently became
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationYou ve come a long way, baby.
COPD Dr Badri Paudel Dept of Medicine GMC/CHRC 4/22/12 badri@gmc 2 You ve come a long way, baby. Wayne McLaren Former Marlboro Man 4/22/12 badri@gmc 3 Age 30 a robust young man Age 51 riding into the sunset
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX COPD OUTLINE Definition and Overview Pathophysiology Diagnosis and Assessment Therapeutic
More informationModern Management of COPD.
Modern Management of COPD. Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP Department of Medicine, Auckland City Hospital and University of Auckland, New Zealand 2 Sponsor Disclaimer
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationObjectives. Objectives. Definition. Physiology. Evaluation of the Dyspneic Patient. B. Celli Disclaimer
Evaluation of the Dyspneic Patient Bartolome R. Celli Harvard Medical School Brigham and Women s Hospital Boston B. Celli Disclaimer No stocks or ownership in any company. No Tobacco funds No promotional
More informationKaren Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health
Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) November 29, 2017 Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health Top 5 Causes of Death
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationA knowledge-based CPE activity presented during the OSHP Annual Meeting
Managing Symptoms and Reducing Exacerbation Risks A knowledge-based CPE activity presented during the OSHP Annual Meeting Thursday, May 3, 2012 Crowne Plaza Columbus North Columbus, OH 11:00 a.m. 12:00
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE DEFINITION Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterized by airflow limitation that is usually progressive
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationFaculty Presenters. Leonard M. Fromer, MD Executive Medical Director Group Practice Forum Los Angeles, California
Faculty Presenters Leonard M. Fromer, MD Executive Medical Director Group Practice Forum Los Angeles, California Frank C. Sciurba, MD Associate Professor of Medicine Medical Director, Pulmonary Physiology
More informationOptimizing COPD Management in Primary Care
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Optimizing COPD Management in Primary Care Sandra Adams, MD, MS Professor, Division of Pulmonary Diseases and Critical Care Medicine
More informationTake My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care
Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More information9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More informationUnderstanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR
Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST
More information